Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).
Biliary Tract Carcinoma
DRUG: Gemcitabine|DRUG: S1|DRUG: Tislelizumab
Objective response rate (ORR), Baseline up to approximately 6 months
Progression free survival (PFS), baseline up to approximately 12 months|1-year survival rate, baseline up to approximately 12 months|Disease control rate (DCR), baseline up to approximately 6 months|Duration of response (DoR), baseline up to approximately 12 months|Percentage of participants with SD â‰¥ 4 weeks, baseline up to approximately 6 months|3-month progression free survival rate, baseline up to approximately 3 months|6-month progression free survival rate, baseline up to approximately 6 months|6-month overall survival rate, baseline up to approximately 6 months|12-month overall survival rate, baseline up to approximately 12 months|Quality of life (QoL), baseline up to approximately 12 months
This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).